# Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

> **NCT04910022** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nerviano Medical Sciences** · enrollment: 150 (estimated)

## Conditions studied

- Glioblastoma
- Diffuse Glioma

## Interventions

- **DRUG:** NMS-03305293
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04910022
- **Lead sponsor:** Nerviano Medical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-09-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910022, "Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04910022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*